LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc., (NASDAQ: CBST) a leading acute care therapeutics company has completed its previously announced acquisition of Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens. Cubist’s agreement to acquire Calixa was announced in a press release issued on Dec. 14th, 2009.
